Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.

Jarvis C, Nelius T, Martinez-Marin D, Sennoune SR, Filleur S.

Prostate. 2018 Sep;78(12):905-914. doi: 10.1002/pros.23647. Epub 2018 May 10.

PMID:
29749077
2.

Novel porcine model for calcium oxalate stone formation.

Trojan BP, Trojan SJ, Navetta A, Staches B, Sutton B, Filleur S, Nelius T.

Int Urol Nephrol. 2017 Oct;49(10):1751-1761. doi: 10.1007/s11255-017-1657-0. Epub 2017 Jul 13.

PMID:
28707190
3.

Renal medullary carcinoma with an ophthalmic metastasis.

Ibilibor C, Medway A, Nelius T.

Urol Ann. 2017 Apr-Jun;9(2):184-187. doi: 10.4103/0974-7796.204184.

4.

PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.

Martinez-Marin D, Jarvis C, Nelius T, de Riese W, Volpert OV, Filleur S.

PLoS One. 2017 Apr 12;12(4):e0174968. doi: 10.1371/journal.pone.0174968. eCollection 2017.

5.

Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.

Nelius T, Martinez-Marin D, Hirsch J, Miller B, Rinard K, Lopez J, de Riese W, Filleur S.

Cell Death Dis. 2014 May 8;5:e1210. doi: 10.1038/cddis.2014.180.

6.

PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.

Wachtel MS, Nelius T, Haynes AL, Dahlbeck S, de Riese W.

Prostate. 2013 Sep;73(12):1365-9. doi: 10.1002/pros.22680. Epub 2013 May 6.

PMID:
23649537
7.

The BioMotionBot: a robotic device for applications in human motor learning and rehabilitation.

Bartenbach V, Sander C, Pöschl M, Wilging K, Nelius T, Doll F, Burger W, Stockinger C, Focke A, Stein T.

J Neurosci Methods. 2013 Mar 15;213(2):282-97. doi: 10.1016/j.jneumeth.2012.12.006. Epub 2012 Dec 28.

PMID:
23276545
8.

The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.

Trojan B, Tang A, Chandrapal J, Filleur S, Nelius T.

Ren Fail. 2013;35(1):72-6. doi: 10.3109/0886022X.2012.741648. Epub 2012 Nov 14.

PMID:
23151051
9.

Positive correlation between PEDF expression levels and macrophage density in the human prostate.

Nelius T, Samathanam C, Martinez-Marin D, Gaines N, Stevens J, Hickson J, de Riese W, Filleur S.

Prostate. 2013 Apr;73(5):549-61. doi: 10.1002/pros.22595. Epub 2012 Oct 4.

10.

A relationship between female genital piercings and genital mutilation?

Nelius T, Armstrong ML, Angel E, Hogan L, Young C, Rinard K.

BJOG. 2012 Jun;119(7):895-6. doi: 10.1111/j.1471-0528.2012.03320.x. No abstract available.

11.

Extraluminal colonic carcinoma invading into kidney: a case report and review of the literature.

Nelson J, Rinard K, Haynes A, Filleur S, Nelius T.

ISRN Urol. 2011;2011:707154. doi: 10.5402/2011/707154. Epub 2011 Apr 26.

12.

Genital piercings: diagnostic and therapeutic implications for urologists.

Nelius T, Armstrong ML, Rinard K, Young C, Hogan L, Angel E.

Urology. 2011 Nov;78(5):998-1007. doi: 10.1016/j.urology.2011.05.066. Review.

PMID:
22054364
13.

TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature.

Nelius T, Al-Khalil I, Vordermark J, Rinard-Holden K, Cammack T, Mamlok V, Filleur S.

Case Rep Med. 2011;2011:432917. doi: 10.1155/2011/432917. Epub 2011 Oct 5.

14.

PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFκB and PPARγ.

Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese Wd, Filleur S.

Cytokine. 2011 Aug;55(2):202-10. doi: 10.1016/j.cyto.2011.04.010. Epub 2011 May 13.

PMID:
21570865
15.

Oral/metronomic cyclophosphamide-based chemotherapy as option for patients with castration-refractory prostate cancer: review of the literature.

Nelius T, Rinard K, Filleur S.

Cancer Treat Rev. 2011 Oct;37(6):444-55. doi: 10.1016/j.ctrv.2010.12.006. Epub 2011 Jan 28. Review.

PMID:
21277093
16.

Cross-sectional study examining four types of male penile and urethral "play".

Rinard K, Nelius T, Hogan L, Young C, Roberts AE, Armstrong ML.

Urology. 2010 Dec;76(6):1326-33. doi: 10.1016/j.urology.2010.03.080. Epub 2010 Jun 25.

PMID:
20579702
17.

INTS6/DICE1 inhibits growth of human androgen-independent prostate cancer cells by altering the cell cycle profile and Wnt signaling.

Filleur S, Hirsch J, Wille A, Schön M, Sell C, Shearer MH, Nelius T, Wieland I.

Cancer Cell Int. 2009 Nov 11;9:28. doi: 10.1186/1475-2867-9-28.

18.

[Self-inflicted penile strangulation].

Nelius T, Filleur S.

Aktuelle Urol. 2010 Jan;41(1):64-6. doi: 10.1055/s-0029-1224690. Epub 2009 Nov 6. German.

PMID:
19899049
19.

PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.

Nelius T, Filleur S.

Prostate. 2009 Dec 1;69(16):1802-7. doi: 10.1002/pros.21024. Review.

PMID:
19676083
20.

Leiomyosarcoma of the urinary bladder presenting as life threatening gross hematuria.

Nelius T, Stevens J, Samathanam C, Filleur S.

Med Oncol. 2010 Jun;27(2):562-7. doi: 10.1007/s12032-009-9248-2. Epub 2009 Jun 11. Review.

PMID:
19517274
21.

Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.

Nelius T, Klatte T, de Riese W, Haynes A, Filleur S.

Med Oncol. 2010 Jun;27(2):363-7. doi: 10.1007/s12032-009-9218-8. Epub 2009 Apr 14.

PMID:
19365737
22.

Transitional cell carcinoma due to chronic UroLume stent irritation.

Paddack J, Leocádio DE, Samathanam C, Nelius T, Haynes A Jr.

Urology. 2009 May;73(5):995-6. doi: 10.1016/j.urology.2008.11.039. Epub 2009 Feb 4.

PMID:
19193405
23.

Characterization of PEDF: a multi-functional serpin family protein.

Filleur S, Nelius T, de Riese W, Kennedy RC.

J Cell Biochem. 2009 Apr 1;106(5):769-75. doi: 10.1002/jcb.22072. Review.

PMID:
19180572
24.

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.

Nelius T, Klatte T, de Riese W, Filleur S.

Int Urol Nephrol. 2008;40(1):97-104. Epub 2007 Jun 30.

PMID:
17602304
25.

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV.

Int J Cancer. 2007 Sep 1;121(5):999-1008.

26.

Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinoma.

Klatte T, Böhm M, Nelius T, Filleur S, Reiher F, Allhoff EP.

BJU Int. 2007 Jul;100(1):209-14. Epub 2007 Apr 8.

27.
28.

[Idiopathic retroperitoneal fibrosis (Ormond's disease)].

Nelius T, Reiher F, Lindenmeir T, Kalinski T, Rau O, Filleur S, Allhoff EP.

Aktuelle Urol. 2006 Jul;37(4):284-8. German.

PMID:
16878283
29.

Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.

Nelius T, Reiher F, Lindenmeir T, Klatte T, Rau O, Burandt J, Filleur S, Allhoff EP.

Onkologie. 2005 Nov;28(11):573-8.

PMID:
16249643
30.

Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV.

Cancer Res. 2005 Jun 15;65(12):5144-52.

31.

In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment.

Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S, Volpert OV, Redondo JM.

Cell Death Differ. 2005 Jun;12(6):649-58.

32.

Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.

Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH, Henkin J, Schneider A, Bouck N, Volpert OV.

Mol Cancer Res. 2004 Oct;2(10):541-50.

33.

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.

34.

Nuclear factor of activated T cells balances angiogenesis activation and inhibition.

Zaichuk TA, Shroff EH, Emmanuel R, Filleur S, Nelius T, Volpert OV.

J Exp Med. 2004 Jun 7;199(11):1513-22.

35.

Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1.

Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM.

Cancer Cell. 2002 Dec;2(6):473-83.

Supplemental Content

Loading ...
Support Center